Dogwood Therapeutics, Inc.
DWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818844
No open-market purchases or sales by Dogwood Therapeutics, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $6.16M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Dogwood Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −1 vs. Q2 2023
- Shares held
- 829.5K
- +47.1K (+6.0%) vs. Q2 2023
- Total value
- $766.3K
- −$312.2K (−28.9%) vs. Q2 2023
- New holders
- 2
- 5 more added
- Sold out
- 3
- 6 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DWTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $6.16M |
| Q1 2026 | 13 | $7.64M |
| Q4 2025 | 10 | $292.0K |
| Q3 2025 | 12 | $299.5K |
| Q2 2025 | 10 | $207.5K |
| Q1 2025 | 13 | $409.8K |
| Q4 2024 | 10 | $76.5K |
| Q3 2024 | 24 | $180.3K |
| Q2 2024 | 24 | $212.0K |
| Q1 2024 | 20 | $324.9K |
| Q4 2023 | 20 | $493.4K |
| Q3 2023 | 23 | $766.3K |
| Q2 2023 | 24 | $1.08M |
| Q1 2023 | 23 | $307.1K |
| Q4 2022 | 27 | $307.7K |
| Q3 2022 | 25 | $485.7K |
| Q2 2022 | 17 | $4.80M |
| Q1 2022 | 15 | $4.91M |
| Q4 2021 | 16 | $4.85M |
| Q3 2021 | 13 | $5.30M |
| Q2 2021 | 14 | $5.58M |
| Q1 2021 | 14 | $5.06M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Dogwood Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 208,883 | $193.2K | 0.00% | −2,113−1.0% | Reduced |
| Geode Capital Management, LLC | 174,469 | $161.4K | 0.00% | +27,200+18.5% | Added |
| Susquehanna International Group, LLP | 102,967 | $95.2K | 0.00% | +50,328+95.6% | Added |
| State Street Corp | 52,828 | $48.9K | 0.00% | 00.0% | Unchanged |
| McCollum Christoferson Group LLC | 33,300 | $30.8K | 0.01% | +2,600+8.5% | Added |
| Simplex Trading, LLC | 31,213 | $28.0K | 0.00% | +9,196+41.8% | Added |
| Raymond James & Associates | 30,000 | $27.7K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 27,322 | $25.0K | 0.00% | +27,322 | New |
| Northern Trust Corp | 24,035 | $22.2K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 22,597 | $20.9K | 0.00% | +22,597 | New |
| Regions Financial Corp | 20,072 | $18.6K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 15,000 | $13.9K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 14,441 | $13.4K | 0.00% | −1,993−12.1% | Reduced |
| Renaissance Technologies LLC | 13,999 | $13.0K | 0.00% | −32,401−69.8% | Reduced |
| Cetera Advisors LLC | 13,560 | $12.5K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 11,482 | $10.6K | 0.00% | −5,131−30.9% | Reduced |
| Wiley Bros.-Aintree Capital, LLC | 11,000 | $10.2K | 0.00% | 00.0% | Unchanged |
| Commonwealth Equity Services, LLC | 10,284 | $10.0K | 0.00% | −5,100−33.2% | Reduced |
| Tower Research Capital LLC (TRC) | 8,770 | $8.11K | 0.00% | +6,484+283.6% | Added |
| Cutler Group LP | 2,300 | $2.00K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 755 | $698 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 124 | $115 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 56 | $0 | 0.00% | −169−75.1% | Reduced |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −33,298−100.0% | Sold out |
| Belvedere Trading LLC | 0 | $0 | 0.00% | −18,142−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −265−100.0% | Sold out |